AI-ECG could catch deadly lung condition before It's too late
NCT ID NCT07079592
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) can detect pulmonary hypertension—a serious condition where blood pressure in the lungs is dangerously high—in people aged 50 to 85 who are at risk. Over 8,600 participants will get the AI-ECG screening; those flagged as high-risk will then receive an echocardiogram to confirm the diagnosis. The goal is to see if this approach leads to earlier detection and better heart and lung outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI-ECG screening tool
What this could lead to
If successful, this AI-ECG could become a quick, low-cost way to screen for pulmonary hypertension, catching it earlier and improving outcomes.
What could go wrong
This is a large but early-stage validation study. The AI may not be accurate enough in real-world settings, and false positives or negatives could limit its usefulness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION, PULMONARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Defense Medical Center
RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••